Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.

doi:10.1182/blood-2015-03-635821

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.

Blood - 26 Nov 2015

Kucine Nicole, Marubayashi Sachie, Bhagwat Neha, Papalexi Efthymia, Koppikar Priya, Sanchez Martin Marta, Dong Lauren, Tallman Marty S, Paietta Elisabeth, Wang Kai, He Jie, Lipson Doron, Stephens Phil, Miller Vince, Rowe Jacob M, Teruya-Feldstein Julie, Mullighan Charles G, Ferrando Adolfo A, Krivtsov Andrei, Armstrong Scott, Leung Laura, Ochiana Stefan O, Chiosis Gabriela, Levine Ross L, Kleppe Maria

Abstract excerpt

The development of the dual Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib for the treatment of myeloproliferative neoplasms (MPNs) has led to studies of ruxolitinib in other clinical contexts, including JAK-mutated acute lymphoblastic leukemia (ALL). However, the limited ability of JAK inhibition to induce molecular or clinicopathological responses in MPNs suggests a need for development of better therapies for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzodioxoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HSP90 Heat-Shock Proteins

Share to Janus Kinase 1

Share to Janus Kinase 2

Share to Neoplasm Proteins

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Purines

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 26443624
DOI: 10.1182/blood-2015-03-635821
PMCID: PMC4661170

Genes

JAK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.PMID 26443624Read ↗

Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative NeoplasmsSemantic proximity Read ↗

Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cellsSemantic proximity Read ↗

HSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative NeoplasmsSemantic proximity Read ↗

Heat shock protein 90Semantic proximity Read ↗

Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.Semantic proximity Read ↗

Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells.Semantic proximity Read ↗

Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT SignalingSemantic proximity Read ↗

IL-6 Activated JAK/STAT3 Pathway and Sensitivity to Hsp90 Inhibitors in Multiple MyelomaSemantic proximity Read ↗

Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors.Semantic proximity Read ↗

Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.Semantic proximity Read ↗

The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathway.Semantic proximity Read ↗

Using Natural Product Inhibitors to Validate Hsp90 as a Molecular Target in CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.